Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 19/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19943884 | 1.00 | SELE (0.68) | SELEKDM4EALDH1A1GLAGAA | |
| SCHEMBL19479238 | 1.00 | SELE (0.68) | SELEKDM4EALDH1A1GLAGAA | |
| SCHEMBL19992245 | 1.00 | SELE (0.68) | SELEKDM4EALDH1A1GLAGAA | |
| SCHEMBL19491792 | 1.00 | SELE (0.68) | SELEKDM4EALDH1A1GLAGAA | |
| SCHEMBL19479344 | 1.00 | SELE (0.68) | SELEKDM4EALDH1A1GLAGAA | |
| SCHEMBL16661822 | 1.00 | SELE (0.68) | SELEKDM4EALDH1A1GLAGAA | |
| SCHEMBL24425681 | 1.00 | SELE (0.68) | SELEKDM4EALDH1A1GLAGAA | |
| SCHEMBL17777237 | 1.00 | SELE (0.68) | SELEKDM4EALDH1A1GLAGAA | |
| SCHEMBL22898069 | 1.00 | SELE (0.68) | SELEKDM4EALDH1A1GLAGAA | |
| SCHEMBL22006978 | 1.00 | SELE (0.68) | SELEKDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332491-B2 | E-selectin antagonist compounds, compositions, and methods of use | GLYCOMIMETICS, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210017215-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLYCOMIMETICS, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-20180066006-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLYCOMIMETICS, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9867841-B2 | Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells | GLYCOMIMETICS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9796745-B2 | E-selectin antagonist compounds, compositions, and methods of use | GLYCOMIMETICS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170296566-A9 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS | GLYCOMIMETICS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332491-B2 | E-selectin antagonist compounds, compositions, and methods of use | SELE, SELPLG, SELP | SELE 1/4885KDM4E 3628/4885ALDH1A1 3541/4885 |
| US-20210017215-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SELE, SELPLG, SELP | SELE 1/4885KDM4E 3628/4885ALDH1A1 3541/4885 |
| US-20180066006-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SELE, SELPLG, SELP | SELE 1/4885KDM4E 3628/4885ALDH1A1 3541/4885 |
| US-20170296566-A9 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS | SELE, SELP, SELPLG | SELE 1/4885KDM4E 4386/4885ALDH1A1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.